Revenue segments as reported by the company.

U.S. Healthcare Solutions

International Healthcare Solutions

Pharmaceutical Distribution Services

Other

Intersegment eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, and administrative

Depreciation and amortization

Employee severance, litigation, and other

Goodwill impairment

Impairment of assets

Acquisition, integration, and restructuring expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cencora Inc

CoreSite Realty Corporation owns, develops, and operates data centers in certain data center markets in the United States, including Los Angeles, the San Francisco Bay and Northern Virginia areas, Chicago, and New York City. Its customer base consists of enterprise customers, communications service providers, media and content companies, government agencies, and educational institutions.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Cencora Inc (COR) excels in Q3, eyes growth through strategic partnerships

Cencora's Q3 performance reflects strong growth and strategic positioning in the healthcare industry. Leveraging its leadership in specialty services, the company aims to capitalize on opportunities through partnerships and customer-centric strategies while addressing challenges in managing key financial factors.

Cencora Inc posts robust fiscal 2024 results, eyes strategic expansion

Cencora Inc's Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and concerns about future challenges. The company's focus on expanding into new specialties and managing potential headwinds demonstrates a proactive approach to growth and risk management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International Healthcare Solutions segment includes pharmaceutical wholesale, related operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Here is how Cencora (COR) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cencora (COR) is a Strong Growth Stock

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Cencora (COR) is a Top Momentum Stock for the Long-Term

COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.

Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y

On Wednesday, Cencora, Inc.'s COR fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the consensus of $77.65 billion.

Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings

Cencora, Inc. (NYSE:COR ) Q4 2024 Earnings Call Transcript November 6, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR Bob Mauch - President and CEO Laz Krikorian - SVP and CAO Conference Call Participants Lisa Gill - JPMorgan Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI George Hill - Deutsche Bank Eric Percher - Nephron Research Stephanie Davis - Barclays Kevin Caliendo - UBS Eric Coldwell - Baird Erin Wright - Morgan Stanley Allen Lutz - Bank of America Charles Rhyee - TD Cowen Operator Hello, everyone, and welcome to today's Cencora Q4 Full Year 2024 Earnings Call. My name is Drew, and I'll be the operator today.

Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Cencora (COR) is a Strong Value Stock

Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.21 per share. This compares to earnings of $2.86 per share a year ago.

Cencora (COR) Tops Q4 Earnings and Revenue Estimates

Drug distributor Cencora said on Wednesday it would acquire Retina Consultants of America (RCA) for $4.6 billion in cash, gaining access to its network of eye specialists.

Cencora to buy Retina Consultants of America for $4.6 bln

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $0.02 for the September quarter of fiscal 2024, compared to $1.72 in the prior year quarter. Adjusted diluted EPS, which is a.

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists, from Webster Equity Partners. “The acquisition of RCA will allow Cencora to broaden our relationships with community providers in a high growth segment and build on our leadership in specialty,” said Bob Mauch, President & CEO of Cencora. “With a.

Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America

COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

Cencora to Report Q4 Earnings: What's in Store for the Stock?

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Fr.

Cencora Expands Enterprise Leadership Team with Two Senior Appointments

Assurant

Costco

Duke Energy

Kellogg

Republic Services

Sempra Energy

Texas Instruments

Verizon

This is the final group of 10 companies scheduled to reach dividend aristocrat status, sometime over the next five years. There are a variety of companies listed, some of whom may not be able to reach the coveted dividend aristocrat title. 3 companies listed below have 10-year dividend growth rates that exceed 10%, and one occasionally provides investors with special dividends every few years.

Dividend Aristocrats Of The Future - Part 3

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

Cencora (COR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

Why Cencora (COR) is a Top Growth Stock for the Long-Term

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

Why Cencora (COR) is a Top Value Stock for the Long-Term

COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.

Cencora Rallies 14.7% Year to Date: What's Driving the Stock?

Cencora (COR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Cencora (COR): Can Its 3.7% Jump Turn into More Strength?

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2024. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &.

News for Cencora Inc Stock (COR)